Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba. Ciudad Universitaria, Córdoba, Argentina.
Drug Dev Ind Pharm. 2021 Jun;47(6):897-907. doi: 10.1080/03639045.2021.1934866. Epub 2021 Jul 16.
The aim of this work was to develop self-microemulsifying lipid-based formulations of -resveratrol in cod liver oil, a long chain lipid, to increase its solubility, dissolution rate and oral bioavailability. Ternary phase diagrams of cod liver oil with surfactant and water as well as pseudo-ternary phase diagrams of the same by mixing cod liver oil (triglyceride) with glycerol monooleate (monoglyeride) were constructed to identify regions where microemulsions were formed. Kolliphor RH 40, Tween 80 and their 1:1-mixtures were evaluated as surfactants. No organic cosolvents were added. It was observed that cod liver oil alone did not form microemulsion with any of the surfactants used, and a 1:1 mixture of cod liver oil and glycerol monooleate was necessary to enable the formation of microemulsion. Among the surfactants, Kolliphor RH 40 provided the maximum microemulsification effect. Several formulations containing 6:4, 1:1, and 4:6 w/w ratios of lipid to surfactant using the 1:1 mixture of cod liver oil and glycerol monooleate as lipid components and Kolliphor RH 40 or its mixture with Tween 80 as surfactants were identified, and -resveratrol solubility in these formulations were determined. Drug concentrations used in the formulations were 80% of saturation solubility, and no organic cosolvents were used in any formulations to increase drug solubility or enable emulsification. dispersion testing in 250 mL of 0.01 N HCl (pH 2) according to the USP method 2 at 50 RPM showed that the formulations rapidly dispersed in aqueous media forming microemulsions and there was no drug precipitation.
这项工作的目的是在鱼肝油(长链脂质)中开发白藜芦醇的自微乳脂质制剂,以提高其溶解度、溶解速率和口服生物利用度。构建了含有表面活性剂和水的鱼肝油三元相图以及通过将鱼肝油(甘油三酯)与甘油单油酸酯(单甘酯)混合的相同的伪三元相图,以确定形成微乳液的区域。评估了 Kolliphor RH 40、Tween 80 及其 1:1 混合物作为表面活性剂。未添加任何有机溶剂。结果表明,单独的鱼肝油与所用的任何表面活性剂都不能形成微乳液,并且需要 1:1 的鱼肝油和甘油单油酸酯混合物才能形成微乳液。在这些表面活性剂中,Kolliphor RH 40 提供了最大的微乳化效果。使用含有 6:4、1:1 和 4:6 w/w 比例的油相与表面活性剂的几种制剂,油相和表面活性剂的比例为 1:1 的混合物,含有 Kolliphor RH 40 或其与 Tween 80 的混合物作为脂质成分,并确定了这些制剂中白藜芦醇的溶解度。制剂中使用的药物浓度为饱和度溶解度的 80%,并且在任何制剂中都未使用有机溶剂来提高药物溶解度或实现乳化。根据 USP 方法 2 在 50 RPM 下在 250 mL 0.01 N HCl(pH 2)中进行的分散测试表明,制剂在水介质中迅速分散形成微乳液,并且没有药物沉淀。